MedPath

Less Toxic, More Personalized Treatments on the Horizon in HER2+ Breast Cancer

Advancements in HER2-positive breast cancer treatment emphasize personalized, less toxic regimens, with trials like APT, ATEMPT, and TRAIN-2 showing high invasive disease-free survival rates and reduced cardiotoxicity. Ongoing trials, such as ATEMPT 2.0 and CompassHER2 RD, aim to further tailor treatments based on individual patient factors and address specific challenges like central nervous system recurrences. The future of HER2-positive breast cancer treatment is focused on personalized medicine and understanding resistance mechanisms to HER2-targeting agents.

Related Clinical Trials

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
ATEMPT 2.0: Adjuvant T-DM1 Vs TH
A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer
A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting
Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study
DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer

Reference News

targetedonc.com
Less Toxic, More Personalized Treatments on the Horizon in HER2+ Breast Cancer

Advancements in HER2-positive breast cancer treatment emphasize personalized, less toxic regimens, with trials like APT, ATEMPT, and TRAIN-2 showing high invasive disease-free survival rates and reduced cardiotoxicity. Ongoing trials, such as ATEMPT 2.0 and CompassHER2 RD, aim to further tailor treatments based on individual patient factors and address specific challenges like central nervous system recurrences. The future of HER2-positive breast cancer treatment is focused on personalized medicine and understanding resistance mechanisms to HER2-targeting agents.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy